Share on LinkedInShare on LinkedIn

ARTICLE · 07 FEBRUARY 2018

Comparative advertising case causes further pain for FMCG giant

Comparative advertisements need to be carefully formed and adequately substantiated to avoid action under the ACL.

AustraliaConsumer Protection

The Federal Court of Australia has found that an advertising campaign by the makers of Nurofen (claiming its product was superior to a competitor's) was misleading and deceptive. This is the second time in recent years that the maker has been under scrutiny for such conduct, with the Court due to make final orders in mid-February 2018. This case, along with the earlier proceedings, highlight the care that should be taken when you and your business consider making public claims about your products and/or services—particularly when comparing products to those of a competitor.

Competitor's campaign shut down

In August 2015, Reckitt Benckiser (Reckitt) commenced a comparative advertising campaign in which Nurofen was compared with Panadol. Reckitt claimed Nurofen and ibuprofen is better, faster acting and more effective than Panadol and paracetamol for delivering pain relief for common headaches. GlaxoSmithKline (GSK), the makers of Panadol, alleged that the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from